Lyell Immunopharma (LYEL) Equity Ratio (2020 - 2025)
Lyell Immunopharma (LYEL) has disclosed Equity Ratio for 6 consecutive years, with 0.73 as the latest value for Q4 2025.
- Quarterly Equity Ratio fell 6.41% to 0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73 through Dec 2025, down 6.41% year-over-year, with the annual reading at 0.73 for FY2025, 6.41% down from the prior year.
- Equity Ratio hit 0.73 in Q4 2025 for Lyell Immunopharma, down from 0.81 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.89 in Q1 2023 to a low of 0.73 in Q4 2025.
- Historically, Equity Ratio has averaged 0.84 across 5 years, with a median of 0.84 in 2022.
- Biggest five-year swings in Equity Ratio: soared 356.07% in 2021 and later decreased 10.69% in 2024.
- Year by year, Equity Ratio stood at 0.82 in 2021, then rose by 7.76% to 0.89 in 2022, then dropped by 1.75% to 0.87 in 2023, then dropped by 10.69% to 0.78 in 2024, then decreased by 6.41% to 0.73 in 2025.
- Business Quant data shows Equity Ratio for LYEL at 0.73 in Q4 2025, 0.81 in Q3 2025, and 0.78 in Q2 2025.